Is medical management of mild autonomous cortisol secretion with cortisol‑lowering drugs an established treatment, and when should it be used?

Medical Management of MACS with Cortisol-Lowering Drugs: Not Yet Established, But Emerging as an Alternative

Medical management of MACS with cortisol-lowering drugs is NOT currently an established treatment according to current guidelines, which recommend either adrenalectomy for select patients or conservative management with annual monitoring. 1 However, emerging evidence suggests medical therapy may offer a viable alternative when surgery is contraindicated, declined by the patient, or in cases of bilateral adrenal disease.

Current Guideline-Based Approach

The 2023 CUA/AUA guidelines clearly state that for patients with mild autonomous cortisol secretion:

• Younger patients with progressive metabolic comorbidities attributable to cortisol excess can be considered for adrenalectomy after shared decision-making 1
• Patients NOT managed surgically should undergo annual clinical screening for new or worsening associated comorbidities 1
• No mention is made of medical therapy as a standard treatment option in these guidelines

When Medical Therapy Could Be Considered (Based on Emerging Evidence)

While not guideline-endorsed, recent research suggests medical therapy may be appropriate in specific scenarios:

Clinical Scenarios for Medical Therapy:

1. Bilateral adrenal disease where surgery would require bilateral adrenalectomy 2
2. Surgery contraindicated due to medical comorbidities
3. Patient declines surgery despite being a candidate 2
4. Elevated baseline blood pressure - particularly systolic hypertension 3
5. Type 2 diabetes requiring better control 3

Available Medications (Off-Label Use):

Metyrapone appears most studied for MACS:

• Low-dose evening dosing (250-500 mg/day) 3
• 40% of patients achieved clinically significant BP improvement (≥5 mmHg reduction in 24-hour systolic BP) 3
• More effective in patients with higher baseline systolic pressure 3
• Improved HbA1c ≥0.5% in diabetic patients without medication changes 3
• Well-tolerated with no reported adrenal insufficiency in studies 3

Mifepristone has also been studied:

• Limited data in MACS specifically 4
• More commonly used in overt Cushing's disease 5

Critical Limitations and Caveats

Major Knowledge Gaps:

• No medications are licensed for MACS treatment 4
• Evidence consists of only small, heterogeneous studies 4
• Only 5 full-text studies exist on medical therapy for MACS 4
• No large prospective randomized trials available 6

Practical Concerns:

• Optimal risk stratification remains challenging 6
• Identification of patients most likely to benefit is unclear 6
• Long-term safety and efficacy data are lacking
• Cost considerations versus surgical intervention 5

Recommended Clinical Algorithm

If considering medical therapy for MACS (off-guideline):

1. Confirm patient is NOT a surgical candidate or has declined surgery
2. Document specific comorbidities: hypertension (especially systolic >140 mmHg), type 2 diabetes, or osteoporosis
3. Consider metyrapone as first-line (250-500 mg evening dosing)
4. Monitor closely:
   • 24-hour ambulatory BP at baseline, 12, and 24 weeks 3
   • HbA1c in diabetic patients
   • Clinical signs of adrenal insufficiency
   • Salivary cortisol rhythms 3
5. Reassess at 24 weeks for clinical benefit
6. Continue annual monitoring as per guidelines even on medical therapy

Bottom Line

Surgery remains the only guideline-endorsed intervention for MACS when treatment is indicated. Medical therapy with cortisol-lowering drugs represents an experimental approach that may benefit select patients who cannot or will not undergo surgery, particularly those with hypertension or diabetes. The evidence base is insufficient to recommend routine medical management, and such treatment should only be undertaken by endocrinologists experienced in managing cortisol excess, with careful patient selection and close monitoring. The urgent need for larger prospective trials is evident 4, and current use should be considered investigational rather than standard practice.